Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer

Share This Post

August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by the Food and Drug Administration for patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) carcinoma (tumours with epicentre 1 to 5 centimetres above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chlamy

Efficacy was assessed in the multicenter, randomised, placebo-controlled trial KEYNOTE-590 (NCT03189719), which involved 749 patients with metastatic or locally advanced esophageal or gastroesophageal junction cancer who were not candidates for surgical resection or final chemoradiation. The PD-L1 IHC 22C3 pharmDx kit was used to assess PD-L1 status in tumour specimens from all patients. Until intolerable toxicity or disease progression, patients were randomised (1:1) to pembrolizumab in combination with cisplatin and fluorouracil or placebo with cisplatin and fluorouracil.

Overall survival (OS) and progression-free survival (PFS) were the primary efficacy end measures, as determined by the investigator using RECIST 1.1. (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ). Patients who were randomised to pembrolizumab with chemotherapy had a statistically significant improvement in OS and PFS. The median OS for the pembrolizumab group was 12.4 months (95 percent confidence interval: 10.5, 14.0), compared to 9.8 months (95 percent confidence interval: 8.8, 10.8) for the chemotherapy arm (HR 0.73; 95 percent confidence interval: 0.62, 0.86; p0.0001). PFS was 6.3 months (95 percent confidence interval: 6.2, 6.9) and 5.8 months (95 percent confidence interval: 5.0, 6.0), respectively (HR 0.65; 95 percent confidence interval: 0.55, 0.76; p0.0001).

Nausea, constipation, diarrhoea, vomiting, stomatitis, fatigue/asthenia, decreased appetite, and weight loss were the most prevalent side effects observed in approximately 20% of patients who received the pembrolizumab combination in KEYNOTE-590.

For esophageal cancer, a dose of 200 mg every three weeks or 400 mg every six weeks is indicated.

 

Reference : https://www.fda.gov/

Check details here.

Take second opinion on gastric cancer treatment


Send Details

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

The Psychological Impact of Liver Transplantation on Patients and Families
Blog

The Psychological Impact of Liver Transplantation on Patients and Families

Liver transplantation is a lifesaving operation, but it comes with huge psychological burdens on patients and their loved ones. From pre-transplant worry to postoperative depression, emotional suffering is the norm along the way. Patients can fear organ rejection, grapple with survivor’s guilt, or develop PTSD. Families also bear considerable stress. Counseling, support groups, and stress management skills play key roles in increasing mental toughness. Dealing with these psychological factors increases recovery and general well-being.

Advances in Liver Transplant Surgery Techniques and Technologies
Cancer

Advances in Liver Transplant Surgery: Techniques and Technologies

Liver transplant surgery has come a long way with advances in minimally invasive procedures, organ preservation, and artificial intelligence. Advances in laparoscopic donor hepatectomy, normothermic machine perfusion, and 3D printing have advanced surgical accuracy and patient outcomes. India has become a world center for liver transplants with state-of-the-art medical facilities available at affordable costs. As success rates have grown, liver transplantation continues to give hope to patients with end-stage liver disease.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟